Ipsen S.A. (OTCMKTS:IPSEY) Short Interest Down 45.5% in May

Ipsen S.A. (OTCMKTS:IPSEY) saw a significant decrease in short interest in May. As of May 31st, there was short interest totalling 600 shares, a decrease of 45.5% from the May 15th total of 1,100 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 1,300 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Ipsen in a research note on Wednesday, April 2nd.

Ipsen Price Performance

Ipsen stock traded up $0.19 during mid-day trading on Friday, reaching $29.84. 465 shares of the company’s stock traded hands, compared to its average volume of 4,699. Ipsen has a 12-month low of $25.11 and a 12-month high of $32.99. The stock has a 50 day moving average of $28.64 and a two-hundred day moving average of $29.24.

Ipsen Increases Dividend

The company also recently announced a dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th will be paid a $0.2896 dividend. The ex-dividend date is Monday, June 9th. This represents a dividend yield of 0.97%. This is an increase from Ipsen’s previous dividend of $0.23.

About Ipsen

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.